Sevelamer carbonate 800 MG Powder for Oral Suspension [Renvela] — RxCUI 861377
RxNorm drug concept · Semantic branded drug
RxCUI 861377
Semantic branded drug · SBD
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI861377
Official nameSevelamer carbonate 800 MG Powder for Oral Suspension [Renvela]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRenvela 0.8 GM Powder for Oral Suspension; Renvela 800 MG Powder for Oral Suspension
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)3,408 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Sevelamer: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- When your kidneys aren't working properly, they can't remove phosphorus from your blood the way they normally would. Dialysis helps, but it doesn't always bring phosphorus down eno...
- What exactly does sevelamer do, and why do I need it if I'm on dialysis?
- Yes, timing really matters here. Sevelamer needs to be taken with each meal because it works by binding to phosphate in the food you're eating right then. If you take it without fo...
- Does it matter when I take it — can I just take all my doses at once?
🕸️ Concept Web — How Sevelamer carbonate 800 MG Powder for Oral Suspe... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sevelamer carbonate 800 MG Powder for Oral Suspension [Renvela]
RxCUI 861377 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Sevelamer
214824IN -
Sevelamer carbonate
660890PIN
-
Sevelamer
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Renvela
749207BN
-
Renvela
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sevelamer Powder for Oral Suspension
1812612SCDF -
Sevelamer carbonate Powder for Oral Suspension
2649266SCDFP -
Sevelamer Oral Powder Product
1812611SCDG -
Sevelamer Oral Product
1159078SCDG -
Sevelamer carbonate Oral Powder Product
2662295SCDGP -
Sevelamer carbonate Oral Product
2663234SCDGP -
Sevelamer Powder for Oral Suspension [Renvela]
1812615SBDF -
Sevelamer carbonate Powder for Oral Suspension [Renvela]
2656825SBDFP - +5 more in this family
-
Sevelamer Powder for Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sevelamer carbonate 800 MG Powder for Oral Suspension
861375SCD -
Sevelamer carbonate 800 MG
749204SCDC -
Sevelamer carbonate 800 MG [Renvela]
749208SBDC
-
Sevelamer carbonate 800 MG Powder for Oral Suspension
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sevelamer carbonate 800 MG Powder for Oral Suspension
SCD · 861375 -
Sevelamer carbonate 800 MG
SCDC · 749204 -
Sevelamer Powder for Oral Suspension
SCDF · 1812612 -
Sevelamer carbonate Powder for Oral Suspension
SCDFP · 2649266 -
Sevelamer Oral Powder Product
SCDG · 1812611 -
Sevelamer Oral Product
SCDG · 1159078 -
Sevelamer carbonate Oral Powder Product
SCDGP · 2662295 -
Sevelamer carbonate Oral Product
SCDGP · 2663234
Brand-Name Concepts
-
Sevelamer carbonate 800 MG [Renvela]
SBDC · 749208 -
Sevelamer Powder for Oral Suspension [Renvela]
SBDF · 1812615 -
Sevelamer carbonate Powder for Oral Suspension [Renvela]
SBDFP · 2656825 -
Renvela Oral Powder Product
SBDG · 1812616 -
Renvela Oral Product
SBDG · 1181332 -
Renvela
BN · 749207
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 861377 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 58468-0131-02 | 90 PACKET in 1 CARTON (58468-0131-2) / 1 POWDER, FOR SUSPEN... | Renvela | Genzyme Corporation | 2009-08-12 |
| 58468-0132-02 | 90 PACKET in 1 CARTON (58468-0132-2) / 1 POWDER, FOR SUSPEN... | Renvela | Genzyme Corporation | 2009-08-12 |
| 58468-0133-01 | 270 TABLET, FILM COATED in 1 BOTTLE (58468-0133-1) | Renvela | Genzyme Corporation | 2023-07-14 |
Observed labelers:
Genzyme Corporation (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.